Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice

The Lancet

Volumn 375, Issue 9729, 2010, Pages 1920-1937

  Wallis, Robert S ^a   Pai, Madhukar ^b,c   Menzies, Dick ^b,c   Doherty, T Mark ^d   Walzl, Gerhard ^e   Perkins, Mark D ^f   Zumla, Alimuddin ^g  

^a PFIZER INC   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d STATENS SERUM INSTITUT   (Denmark)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^g ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; LATENT TUBERCULOSIS; LIGHT EMITTING DIODE; LIQUID CULTURE; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; RECURRENCE RISK; REVIEW; SPUTUM CULTURE; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

EID: 77952892091     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60359-5     Document Type: Review

References (218)

1. Biomarkers working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001) 89-95
2. Mitchison D.A. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 147 (1993) 1062-1063
3. The Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360 (2002) 528-534
4. Wallis R.S., Wang C., Doherty T.M., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 10 (2010) 68-69
5. Rustomjee R., Diacon A.H., Allen J., et al. Early bactericidal activity and pharmacokinetics of the Diarylquinoline TMC 207 in pulmonary tuberculosis. Antimicrob Agents Chemother 52 (2008) 2831-2835
6. Davies G.R., Brindle R., Khoo S.H., and Aarons L.J. Use of nonlinear mixed-effects analysis for improved precision of early pharmacodynamic measures in tuberculosis treatment. Antimicrob Agents Chemother 50 (2006) 3154-3156
7. Epstein M.D., Schluger N.W., Davidow A.L., Bonk S., Rom W.N., and Hanna B. Time to detection of Mtb tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. Chest 113 (1998) 379-386
8. Wallis R.S., Perkins M., Phillips M., et al. Induction of the antigen 85 complex of M. tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis. J Infect Dis 178 (1998) 1115-1121
9. Rustomjee R., Lienhardt C., Kanyok T., et al. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12 (2008) 128-138
10. Wallis R.S., Perkins M., Phillips M., et al. Predicting the outcome of therapy for pulmonary tuberculosis. Am J Respir Crit Care Med 161 (2000) 1076-1080
11. Wallis R.S., Phillips M., Johnson J.L., et al. Inhibition of INH-induced expression of M. tuberculosis antigen 85 in sputum: a potential surrogate marker in TB chemotherapy trials. Antimicrob Agents Chemother 45 (2001) 1302-1304
12. Desjardin L.E., Perkins M.D., Wolski K., et al. Measurement of sputum Mtb tuberculosis messenger RNA as a surrogate for response to chemotherapy. Am J Respir Crit Care Med 160 (1999) 203-210
13. Li L., Mahan C.S., Palaci M., et al. Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to anti-tuberculosis therapy. J Clin Microbiol 48 (2010) 46-51
14. Garton N.J., Waddell S.J., Sherratt A.L., et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 5 (2008) e75
15. Cannas A., Goletti D., Girardi E., et al. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. Int J Tuberc Lung Dis 12 (2008) 146-151
16. Cannas A, Calvo L, Chiacchio T, et al. Mycobacterium tuberculosis DNA detection in the urine from pulmonary tuberculosis patients (abstract). Seventh International Conference on the Pathogenesis of Mycobacterial Infections; June, 2008; Saltsjobaden, Sweden (abstr P17: 39).
17. Shah M., Variava E., Holmes C.B., et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 52 (2009) 145-151
18. Mutetwa R., Boehme C., Dimairo M., et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis 13 (2009) 1253-1259
19. Reither K., Saathoff E., Jung J., et al. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis 9 (2009) 141
20. Daley P., Michael J.S., Hmar P., et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis 13 (2009) 989-995
21. Boehme C., Molokova E., Minja F., et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg 99 (2005) 893-900
22. Tessema T.A., Bjune G., Assefa G., Svenson S., Hamasur B., and Bjorvatn B. Clinical and radiological features in relation to urinary excretion of lipoarabinomannan in Ethiopian tuberculosis patients. Scand J Infect Dis 34 (2002) 167-171
23. Choudhry V., and Saxena R.K. Detection of Mycobacterium tuberculosis antigens in urinary proteins of tuberculosis patients. Eur J Clin Microbiol Infect Dis 21 (2002) 1-5
24. Singh K.K., Dong Y., Hinds L., et al. Combined use of serum and urinary antibody for diagnosis of tuberculosis. J Infect Dis 188 (2003) 371-377
25. Kashino S.S., Pollock N., Napolitano D.R., Rodrigues Jr. V., and Campos-Neto A. Identification and characterization of Mycobacterium tuberculosis antigens in urine of patients with active pulmonary tuberculosis: an innovative and alternative approach of antigen discovery of useful microbial molecules. Clin Exp Immunol 153 (2008) 56-62
26. Napolitano D.R., Pollock N., Kashino S.S., Rodrigues Jr. V., and Campos-Neto A. Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis. Clin Vaccine Immunol 15 (2008) 638-643
27. Syhre M., and Chambers S.T. The scent of Mycobacterium tuberculosis. Tuberculosis (Edinb) 88 (2008) 317-323
28. Phillips M., Cataneo R.N., Condos R., et al. Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis (Edinb) 87 (2007) 44-52
29. Wallis R.S., Palaci M., Vinhas S., et al. A whole blood bactericidal assay for tuberculosis. J Infect Dis 183 (2001) 1300-1303
30. Janulionis E., Sofer C., Song H.Y., and Wallis R.S. Lack of activity of oral clofazimine against intracellular M. tuberculosis in whole blood culture. Antimicrob Agents Chemother 48 (2004) 3133-3135
31. Wallis R.S., Vinhas S.A., Johnson J.L., et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 187 (2003) 270-278
32. Veenstra H., Crous I., Brahmbhatt S., et al. Changes in the kinetics of intracellular IFN-gamma production in TB patients during treatment. Clin Immunol 124 (2007) 336-344
33. Carrara S., Vincenti D., Petrosillo N., Amicosante M., Girardi E., and Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 38 (2004) 754-756
34. Sauzullo I., Mengoni F., Lichtner M., et al. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. PLoS One 4 (2009) e5187
35. Aiken A.M., Hill P.C., Fox A., et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 6 (2006) 66
36. Kobashi Y., Mouri K., Yagi S., Obase Y., Miyashita N., and Oka M. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect 58 (2009) 197-204
37. Ribeiro S., Dooley K., Hackman J., et al. T-SPOT.TB responses during treatment of pulmonary tuberculosis. BMC Infect Dis 9 (2009) 23
38. Wassie L., Demissie A., Aseffa A., et al. Ex vivo cytokine mRNA levels correlate with changing clinical status of ethiopian TB patients and their contacts over time. PLoS One 3 (2008) e1522
39. Dheda K., Chang J.S., Breen R.A., et al. In vivo and in vitro studies of a novel cytokine, interleukin 4delta2, in pulmonary tuberculosis. Am J Respir Crit Care Med 172 (2005) 501-508
40. Siawaya J.F., Bapela N.B., Ronacher K., Beyers N., van Helden P., and Walzl G. Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment. Clin Vaccine Immunol 15 (2008) 1165-1170
41. Wallis R.S., Helfand M.S., Whalen C., et al. Immune activation, allergic drug toxicity, and mortality in HIV-positive tuberculosis. Tuber Lung Dis 77 (1996) 516-523
42. Immanuel C., Rajeswari R., Rahman F., Kumaran P.P., Chandrasekaran V., and Swamy R. Serial evaluation of serum neopterin in HIV seronegative patients treated for tuberculosis. Int J Tuberc Lung Dis 5 (2001) 185-190
43. Turgut T., Akbulut H., Deveci F., Kacar C., and Muz M.H. Serum interleukin-2 and neopterin levels as useful markers for treatment of active pulmonary tuberculosis. Tohoku J Exp Med 209 (2006) 321-328
44. Hosp M., Elliott A.M., Raynes J.G., et al. Neopterin, beta 2-microglobulin, and acute phase proteins in HIV-1-seropositive and -seronegative Zambian patients with tuberculosis. Lung 175 (1997) 265-275
45. Fuchs D., Hausen A., Kofler M., Kosanowski H., Reibnegger G., and Wachter H. Neopterin as an index of immune response in patients with tuberculosis. Lung 162 (1984) 337-346
46. Baylan O., Balkan A., Inal A., et al. The predictive value of serum procalcitonin levels in adult patients with active pulmonary tuberculosis. Jpn J Infect Dis 59 (2006) 164-167
47. Nyamande K., and Lalloo U.G. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 10 (2006) 510-515
48. Polzin A., Pletz M., Erbes R., et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 21 (2003) 939-943
49. Prat C., Dominguez J., Andreo F., et al. Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 52 (2006) 169-177
50. Schleicher G.K., Herbert V., Brink A., et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J 25 (2005) 688-692
51. Kandemir O., Uluba B., Polat G., Sezer C., Camdeviren H., and Kaya A. Elevation of procalcitonin level in patients with pulmonary tuberculosis and in medical staff with close patient contact. Arch Med Res 34 (2003) 311-314
52. Wallis R.S., van Vuuren C., and Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 48 (2009) 1429-1432
53. Tang B.M., Eslick G.D., Craig J.C., and McLean A.S. Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7 (2007) 210-217
54. Lawn S.D., Wiktor S., Coulibaly D., Ackah A.N., and Lal R.B. Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus. Trans R Soc Trop Med Hyg 95 (2001) 41-42
55. Bajaj G., Rattan A., and Ahmad P. Prognostic value of 'C' reactive protein in tuberculosis. Indian Pediatr 26 (1989) 1010-1013
56. Scott G.M., Murphy P.G., and Gemidjioglu M.E. Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein. J Infect 21 (1990) 61-69
57. Plit M.L., Theron A.J., Fickl H., Van Rensburg C.E., Pendel S., and Anderson R. Influence of antimicrobial chemotherapy and smoking status on the plasma concentrations of vitamin C, vitamin E, beta-carotene, acute phase reactants, iron and lipid peroxides in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2 (1998) 590-596
58. Lee J.H., and Chang J.H. Changes of plasma interleukin-1 receptor antagonist, interleukin-8 and other serologic markers during chemotherapy in patients with active pulmonary tuberculosis. Korean J Intern Med 18 (2003) 138-145
59. Baynes R., Bezwoda W., Bothwell T., Khan Q., and Mansoor N. The non-immune inflammatory response: serial changes in plasma iron, iron-binding capacity, lactoferrin, ferritin and C-reactive protein. Scand J Clin Lab Invest 46 (1986) 695-704
60. Walzl G., Ronacher K., Siawaya J.D., and Dockrell H.M. Biomarkers for TB treatment response: Challenges and future strategies. J Infect 57 (2008) 103-109
61. Lai C.K., Wong K.C., Chan C.H., et al. Circulating adhesion molecules in tuberculosis. Clin Exp Immunol 94 (1993) 522-526
62. Demir T., Yalcinoz C., Keskinel I., Demiroz F., and Yildirim N. sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. Int J Tuberc Lung Dis 6 (2002) 155-159
63. Mukae H., Ashitani J., Tokojima M., Ihi T., Kohno S., and Matsukura S. Elevated levels of circulating adhesion molecules in patients with active pulmonary tuberculosis. Respirology 8 (2003) 326-331
64. Siawaya J.D., Bapela N.B., Ronacher K., et al. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. J Infect 56 (2008) 340-347
65. Eugen-Olsen J., Gustafson P., Sidenius N., et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 6 (2002) 686-692
66. Rosas-Taraco A.G., Salinas-Carmona M.C., Revol A., Rendon A., Caballero-Olin G., and Arce-Mendoza A.Y. Expression of CDllc in blood monocytes as biomarker for favorable response to antituberculosis treatment. Arch Med Res 40 (2009) 128-131
67. Agranoff D., Fernandez-Reyes D., Papadopoulos M.C., et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 368 (2006) 1012-1021
68. Brahmbhatt S., Black G.F., Carroll N.M., et al. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy. Clin Exp Immunol 146 (2006) 243-252
69. Mistry R., Cliff J.M., Clayton C., et al. Gene expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis 195 (2007) 357-365
70. Jacobsen M., Repsilber D., Gutschmidt A., et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med 85 (2007) 613-621
71. Lalvani A., Pathan A.A., Durkan H., et al. Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Lancet 357 (2001) 2017-2021
72. Jackson-Sillah D., Hill P.C., Fox A., et al. Screening for tuberculosis among 2381 household contacts of sputum-smear-positive cases in The Gambia. Trans R Soc Trop Med Hyg 101 (2007) 594-601
73. Bakir M., Millington K.A., Soysal A., et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 149 (2008) 777-787
74. Aichelburg M.C., Rieger A., Breitenecker F., et al. Detection and prediction of active tuberculosis disease by a whole-blood interferon-gamma release assay in HIV-1-infected individuals. Clin Infect Dis 48 (2009) 954-962
75. Doherty T.M., Demissie A., Olobo J., et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients. J Clin Microbiol 40 (2002) 704-706
76. Diel R., Loddenkemper R., Meywald-Walter K., Niemann S., and Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177 (2008) 1164-1170
77. Higuchi K., Harada N., Fukazawa K., and Mori T. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. Tuberculosis (Edinb) 88 (2008) 244-248
78. Petrucci R., Abu A.N., Gurgel R.Q., et al. Interferon gamma, interferon-gamma-induced-protein 10, and tuberculin responses of children at high risk of tuberculosis infection. Pediatr Infect Dis J 27 (2008) 1073-1077
79. Whittaker E., Gordon A., and Kampmann B. Is IP-10 a better biomarker for active and latent tuberculosis in children than IFNgamma?. PLoS ONE 3 (2008) e3901
80. Ruhwald M., Bjerregaard-Andersen M., Rabna P., Eugen-Olsen J., and Ravn P. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res Notes 2 (2009) 19
81. Demissie A., Wassie L., Abebe M., et al. The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon. Infect Immun 74 (2006) 2817-2822
82. Demissie A., Abebe M., Aseffa A., et al. Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th1 cytokines and the IL-4 antagonist IL-4delta2. J Immunol 172 (2004) 6938-6943
83. Weldingh K., and Andersen P. ESAT-6/CFP10 skin test predicts disease in M. tuberculosis-infected guinea pigs. PLoS One 3 (2008) e1978
84. Edwards L.B., Acquaviva F.A., and Livesay V.T. Identification of tuberculous infected: dual tests and density of reaction. Am Rev Respir Dis 108 (1973) 1334-1339
85. Ozdemir D., Cesur S., Annakkaya A.N., et al. Serum neopterin concentrations in healthy healthcare workers compared with healthy controls and patients with pulmonary tuberculosis. Med Sci Monit 12 (2006) CR521-CR524
86. Hoft D.F., Blazevic A., Abate G., et al. A new recombinant bacille Calmette-Guerin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198 (2008) 1491-1501
87. Soares A.P., Scriba T.J., Joseph S., et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 180 (2008) 3569-3577
88. Hawkridge T., Scriba T.J., Gelderbloem S., et al. Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Healthy Adults in South Africa. J Infect Dis 198 (2008) 544-552
89. Davids V., Hanekom W.A., Mansoor N., et al. The effect of bacille calmette-guerin vaccine strain and route of administration on induced immune responses in vaccinated infants. J Infect Dis 193 (2006) 531-536
90. Hanekom W.A., Hughes J., Mavinkurve M., et al. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J Immunol Methods 291 (2004) 185-195
91. Kampmann B., Gaora P.O., Snewin V.A., Gares M.P., Young D.B., and Levin M. Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. J Infect Dis 182 (2000) 895-901
92. Cheon S.H., Kampmann B., Hise A.G., et al. Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol 9 (2002) 901-907
93. Kampmann B., Tena G.N., Mazazi S., Young D., Eley B., and Levin M. A novel human in vitro system to evaluate antimycobacterial vaccines. Infect Immun 72 (2004) 6401-6407
94. Tena G.N., Young D.B., Eley B., et al. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus, and its relationship to T cell function. J Infect Dis 187 (2003) 1544-1551
95. Kampmann B., Tena-Coki G.N., Nicol M., Levin M., and Eley B. Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS 20 (2006) 1011-1018
96. Martineau A.R., Wilkinson R.J., Wilkinson K.A., et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 176 (2007) 208-213
97. Saliu O., Sofer C., Stein D.S., Schwander S.K., and Wallis R.S. Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J Infect Dis 194 (2006) 486-492
98. Hoft D.F., Worku S., Kampmann B., et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective mycobacterium tuberculosis immunity. J Infect Dis 186 (2002) 1448-1457
99. Wallis R.S., Vinhas S., and Janulionis E. Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. Tuberculosis (Edinb) 89 (2009) 221-224
100. Canaday D.H., Wilkinson R.J., Li Q., Harding C.V., Silver R.F., and Boom W.H. CD4(+) and CD8(+) T cells kill intracellular Mycobacterium tuberculosis by a perforin and Fas/Fas ligand-independent mechanism. J Immunol 167 (2001) 2734-2742
101. Cheng S.H., Walker L., Poole J., et al. Demonstration of increased anti-mycobacterial activity in peripheral blood monocytes after BCG vaccination in British school children. Clin Exp Immunol 74 (1988) 20-25
102. Conde M.B., Efron A., Loredo C., et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373 (2009) 1183-1189
103. Dorman S.E., Johnson J.L., Goldberg S., et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180 (2009) 273-280
104. Burman W.J., Goldberg S., Johnson J.L., et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174 (2006) 331-338
105. Nuermberger E.L., Yoshimatsu T., Tyagi S., et al. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170 (2004) 1131-1134
106. Rebollo M.J., Juan G.S., Folgueira D., et al. Blood and urine samples as useful sources for the direct detection of tuberculosis by polymerase chain reaction. Diagn Microbiol Infect Dis 56 (2006) 141-146
107. Torrea G., Van de Perre P., Ouedraogo M., et al. PCR-based detection of the Mycobacterium tuberculosis complex in urine of HIV-infected and uninfected pulmonary and extrapulmonary tuberculosis patients in Burkina Faso. J Med Microbiol 54 (2005) 39-44
108. Kafwabulula M., Ahmed K., Nagatake T., et al. Evaluation of PCR-based methods for the diagnosis of tuberculosis by identification of mycobacterial DNA in urine samples. Int J Tuberc Lung Dis 6 (2002) 732-737
109. Aceti A., Zanetti S., Mura M.S., et al. Identification of HIV patients with active pulmonary tuberculosis using urine based polymerase chain reaction assay. Thorax 54 (1999) 145-146
110. Kumar V., Jakubiec W., Li X., et al. Safety, tolerability, pk, and whole blood bactericidal activity (WBA) against Mycobacterium tuberculosis of single ascending doses of PNU-100480. ICAAC 49 (2009) F1a-F1217a (abstr).
111. Williams K.N., Stover C.K., Zhu T., et al. Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother 53 (2008) 1314-1319
112. Kim K., Visintin I., Alvero A.B., and Mor G. Development and validation of a protein-based signature for the detection of ovarian cancer. Clin Lab Med 29 (2009) 47-55
113. Chee C.B., KhinMar K.W., Gan S.H., et al. Effect of TB treatment on T-cell interferon-{gamma} responses to M. tb-specific antigens. Eur Respir J (2009) 10.1183/09031936.00151309 published online Nov 19.
114. Jafari C., Thijsen S., Sotgiu G., et al. Bronchoalveolar lavage enzyme-linked immunospot for a rapid diagnosis of tuberculosis: a Tuberculosis Network European Trials group study. Am J Respir Crit Care Med 180 (2009) 666-673
115. Losi M., Bossink A., Codecasa L., et al. Use of a T-cell interferon-gamma release assay for the diagnosis of tuberculous pleurisy. Eur Respir J 30 (2007) 1173-1179
116. Thomas M.M., Hinks T.S., Raghuraman S., et al. Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. Int J Tuberc Lung Dis 12 (2008) 651-657
117. Azzurri A., Kanaujia G.V., Sow O.Y., et al. Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea. Int J Immunopathol Pharmacol 19 (2006) 199-208
118. Silva V.M., Sardella I.G., Luiz R.R., et al. Immunoreactivity of five antigens of Mycobacterium tuberculosis in patients attending a public health care facility in an area with high endemicity for TB. Microbiol Immunol 52 (2008) 544-550
119. Geldmacher C., Schuetz A., Ngwenyama N., et al. Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis 198 (2008) 1590-1598
120. Ewer K., Millington K.A., Deeks J.J., Alvarez L., Bryant G., and Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 174 (2006) 831-839
121. Higuchi K., Harada N., and Mori T. Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. Respirology 13 (2008) 468-472
122. Chee C.B., KhinMar K.W., Gan S.H., Barkham T.M., Pushparani M., and Wang Y.T. Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens. Am J Respir Crit Care Med 175 (2007) 282-287
123. Herrmann J.L., Belloy M., Porcher R., et al. Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS One 4 (2009) e4130
124. Pai M., Joshi R., Dogra S., et al. Serial testing of health care workers for tuberculosis using interferon-{gamma} assay. Am J Respir Crit Care Med 174 (2006) 349-355
125. Pai M., Joshi R., Dogra S., et al. Persistently elevated T cell interferon-g responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report. J Occup Med Toxicol 1 (2006) 7
126. Wilkinson K.A., Kon O.M., Newton S.M., et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. J Infect Dis 193 (2006) 354-359
127. Goletti D., Parracino M.P., Butera O., et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. Respir Res 8 (2007) 5
128. Elias D., Akuffo H., and Britton S. PPD induced in vitro interferon gamma production is not a reliable correlate of protection against Mycobacterium tuberculosis. Trans R Soc Trop Med Hyg 99 (2005) 363-368
129. Darrah P.A., Patel D.T., De Luca P.M., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13 (2007) 843-850
130. Hawkridge A., Hatherill M., Little F., et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337 (2008) a2052
131. Floto R.A., MacAry P.A., Boname J.M., et al. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science 314 (2006) 454-458
132. Electronic Code of Federal Regulations. Title 21: food and drugs. Subpart H-accelerated approval of new drugs for serious or life-threatening illnesses (March, 2010). http://ecfr.gpoaccess.gov/cgi/t/text/text-idx?c=ecfr&sid=783fca020c8 214aec9e6fb4cc4871278&rgn=div6&view=text&node=21:5.0.1.1.4.8 &idno=21 (accessed March 26, 2010).
133. US Department of Health and Human Services, and Food and Drug Administartion. Innovation or stagnation: challenge and opportunity on the critical path to new medical products (2004), Food and Drug Administration, Bethesda. http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/Budget Reports/2006FDABudgetSummary/UCM148086.pdf (accessed March 26, 2010).
134. Zerhouni E. Medicine. The NIH Roadmap. Science 302 (2003) 63-72
135. Wagner J.A. Overview of biomarkers and surrogate endpoints in drug development. Dis Markers 18 (2002) 41-46
136. Lathia C.D., Amakye D., Dai W., et al. The value, qualification, and regulatory use of surrogate end points in drug development. Clin Pharmacol Ther 86 (2009) 32-43
137. Lönnroth K., Castro K.G., Chakaya J.M., et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet (2010) 10.1016/S0140-6736(10)60483-7 published online May 19.
138. Davies P.D., and Pai M. The diagnosis and misdiagnosis of tuberculosis. Int J Tuberc Lung Dis 12 (2008) 1226-1234
139. Perkins M.D., and Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 196 suppl 1 (2007) S15-S27
140. Getahun H., Harrington M., O'Brien R., and Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 369 (2007) 2042-2049
141. Reid M.J., and Shah N.S. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 9 (2009) 173-184
142. Perkins M.D., and Small P.M. Partnering for better microbial diagnostics. Nat Biotechnol 24 (2006) 919-921
143. WHO. Special Programme for Researchand Training in Tropical Diseases (TDR) and Foundation for Innovative New Diagnostics (FIND). Diagnostics for tuberculosis. Global demand and market potential (2006), World Health Organization, Geneva
144. Vitoria M., Granich R., Gilks C.F., et al. The global fight against HIV/AIDS, tuberculosis, and malaria: current status and future perspectives. Am J Clin Pathol 131 (2009) 844-848
145. Perkins M.D., and Bell D.R. Working without a blindfold: the critical role of diagnostics in malaria control. Malar J 7 suppl 1 (2008) S5
146. Girardi E., Sabin C.A., and Monforte A.D. Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing. J Acquir Immune Defic Syndr 46 suppl 1 (2007) S3-S8
147. WHO. Global tuberculosis control 2009-epidemiology, strategy, financing (2009), World Health Organization, Geneva
148. Wallis R.S., Doherty T.M., Onyebujoh P., et al. Biomarkers for tuberculosis disease activity, cure and relapse. Lancet Infect Dis 9 (2009) 162-172
149. Young D.B., Perkins M.D., Duncan K., and Barry III C.E. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 118 (2008) 1255-1265
150. Kaufmann S.H. How can immunology contribute to the control of tuberculosis?. Nat Rev Immunol 1 (2001) 20-30
151. Young D.B., Gideon H.P., and Wilkinson R.J. Eliminating latent tuberculosis. Trends Microbiol 17 (2009) 183-188
152. Barry III C.E., Boshoff H.I., Dartois V., et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7 (2009) 845-855
153. Mack U., Migliori G.B., Sester M., et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 33 (2009) 956-973
154. Andersen P., Doherty T.M., Pai M., and Weldingh K. The prognosis of latent tuberculosis: can disease be predicted?. Trend Mol Med 13 (2007) 175-182
155. Pai M. Spectrum of latent tuberculosis: existing tests cannot resolve underlying phenotypes. Nat Rev Microbiol 8 (2010) 242
156. Hill P.C., Jackson-Sillah D.J., Fox A., et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 3 (2008) e1379
157. Bakir M., Millington K.A., Soysal A., et al. Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact. Ann Intern Med 149 (2008) 777-787
158. Diel R., Loddenkemper R., Meywald-Walter K., Niemann S., and Nienhaus A. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. Am J Respir Crit Care Med 177 (2008) 1164-1170
159. Kik S.V., Franken W.P., Mensen M., et al. Predictive value for progression to tuberculosis by IGRA and TST in immigrant contacts. Eur Respir J (2009) 10.1183/09031936.00098509 published online Oct 19.
160. del Corral H., Paris S.C., Marin N.D., et al. IFNg response to Mycobacterium tuberculosis, risk of infection and disease in household contacts of tuberculosis patients in Colombia. PLoS One 4 (2009) e8257
161. Sandgren A., Strong M., Muthukrishnan P., Weiner B.K., Church G.M., and Murray M.B. Tuberculosis drug resistance mutation database. PLoS Med 6 (2009) e2
162. Pai M., and O'Brien R. New diagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 29 (2008) 560-568
163. Perkins M.D., Roscigno G., and Zumla A. Progress towards improved tuberculosis diagnostics for developing countries. Lancet 367 (2006) 942-943
164. WHO. Rapid tests for drug-resistant TB to be available in developing countries (2008), World Health Organization, Geneva. http://www.who.int/tb/features_archive/mdrtb_rapid_tests/en/index.html (accessed Feb 3, 2010).
165. Wenner M. New plan seeks to accelerate African diagnostic capacity. Nat Med 15 (2009) 978
166. WHO and Stop TB Partnership. New laboratory diagnostic tools for tuberculosis control (2008), World Health Organization, Geneva
167. Stop TB Partnership and WHO. The Global Plan to Stop TB 2006-2015 (2006), World Health Organization, Geneva
168. Pai M., Minion J., Sohn H., Zwerling A., and Perkins M. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 30 (2009) 701-716
169. WHO. The use of liquid medium for culture and DST (2007), World Health Organization, Geneva. http://www.who.int/tb/research/retooling/en/index.html (accessed March 24, 2010).
170. WHO. Policy statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB) (2008), World Health Organization, Geneva. http://www.who.int/tb/features_archive/policy_statement.pdf (accessed Feb 3, 2010).
171. WHO. Report of the 9th meeting of the Strategic and Technical Advisory Group on Tuberculosis (STAG-TB) (2009), World Health Organization, Geneva. http://www.who.int/tb/advisory_bodies/stag/en/index.html (accessed March 24, 2010).
172. Pai M., Ramsay A., and O'Brien R. Evidence-based tuberculosis diagnosis. PLoS Med 5 (2008) e156
173. WHO. Reduction of number of smears for the diagnosis of pulmonary TB (2008), World Health Organization, Geneva. http://www.who.int/tb/dots/laboratory/policy/en/index2.html (accessed Feb 3, 2010).
174. WHO. Definition of a new sputum smear-positive TB case (2008), World Health Organization, Geneva. http://www.who.int/tb/dots/laboratory/policy/en/index1.html (accessed Feb 3, 2010).
175. Ling D.I., Zwerling A., and Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32 (2008) 1165-1174
176. Steingart K.R., Henry M., Ng V., et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 6 (2006) 570-581
177. Minion J., Sohn H., and Pai M. Light-emitting diode technologies for TB diagnosis: what's on the market?. Expert Rev Med Devices 6 (2009) 341-345
178. Ramsay A., Cuevas L.E., Mundy C.J., et al. New policies, new technologies: modelling the potential for improved smear microscopy services in Malawi. PLoS One 4 (2009) e7760
179. WHO. Moving research findings into new WHO policies (2008), World Health Organization, Geneva. http://www.who.int/tb/dots/laboratory/policy/en/index4.html (accessed Feb 3, 2010).
180. Stop TB Partnership's New Diagnostics Working Group and WHO. Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics (2009), World Health Organization, Geneva. http://www.stoptb.org/wg/new_diagnostics/ (accessed March 24, 2010).
181. Pai M., Ramsay A., and O'Brien R. Comprehensive new resource for evidence-based TB diagnosis. Expert Rev Mol Diagn 9 (2009) 637-639
182. Helb D., Jones M., Story E., et al. Rapid detection of Mycobacterium tuberculosis and rifampicin-resistance using on-demand, near patient technology. J Clin Microbiol 48 (2010) 229-237
183. Pai M., Zwerling A., and Menzies D. T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 149 (2008) 177-184
184. Pai M. Guidelines on IGRAs: concordant or discordant? 2nd global symposium on IGRAs; Dubrovnik, Croatia (2009). http://www.igrasymposium.com/agenda.html (accessed March 24, 2010).
185. Reid A., Scano F., Getahun H., et al. Towards universal access to HIV prevention, treatment, care, and support: the role of tuberculosis/HIV collaboration. Lancet Infect Dis 6 (2006) 483-495
186. Hopewell P.C., Pai M., Maher D., Uplekar M., and Raviglione M.C. International standards for tuberculosis care. Lancet Infect Dis 6 (2006) 710-725
187. Yager P., Domingo G.J., and Gerdes J. Point-of-care diagnostics for global health. Ann Rev Biomed Eng 10 (2008) 107-144
188. Usdin M., Guillerm M., and Chirac P. Neglected tests for neglected patients. Nature 441 (2006) 283-284
189. Médecins Sans Frontières. Paris meeting on TB point-of-care test specifications (2009). http://www.msfaccess.org/TB_POC_Parismeeting/ (accessed March 24, 2010).
190. Marais B.J., and Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev 8 (2007) 124-133
191. Steingart K.R., Dendukuri N., Henry M., et al. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol 16 (2009) 260-276
192. Steingart K.R., Henry M., Laal S., et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 4 (2007) e202
193. Daley P., Michael J.S., Hmar P., et al. Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study. Int J Tuberc Lung Dis 13 (2009) 989-995
194. Mutetwa R., Boehme C., Dimairo M., et al. Diagnostic accuracy of commercial urinary lipoarabinomannan detection in African tuberculosis suspects and patients. Int J Tuberc Lung Dis 13 (2009) 1253-1259
195. Reither K., Saathoff E., Jung J., et al. Low sensitivity of a urine LAM-ELISA in the diagnosis of pulmonary tuberculosis. BMC Infect Dis 9 (2009) 141
196. Shah M., Variava E., Holmes C.B., et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 52 (2009) 145-151
197. Lawn S.D., Edwards D., Kranzer K., Vogt M., Bekker L.G., and Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 23 (2009) 1875-1880
198. Green C., Huggett J.F., Talbot E.A., Mwaba P., Reither K., and Zumla A.I. Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods. Lancet Infect Dis 9 (2009) 505-511
199. Fontela P.S., Pai N.P., Schiller I., Dendukuri N., Ramsay A., and Pai M. Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards. PLoS One 4 (2009) e7753
200. Sohn H., Minion J., Albert H., Dheda K., and Pai M. TB diagnostic tests: how do we figure out their costs?. Exp Rev Anti-infective Ther 7 (2009) 723-733
201. Stop TB Partnership. TB Research Movement (2008). http://www.stoptb.org/researchmovement (accessed Feb 3, 2010).
202. Guyatt G.H., Oxman A.D., Vist G.E., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336 (2008) 924-926
203. Schunemann H.J., Oxman A.D., Brozek J., et al. GRADE: assessing the quality of evidence for diagnostic recommendations. Evid Based Med 13 (2008) 162-163
204. Schunemann H.J., Oxman A.D., Brozek J., et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 336 (2008) 1106-1110
205. Pai M., Minion J., Steingart K.R., and Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice and impact. Curr Opin Pulm Med 16 (2010) 271-284
206. Chaisson R.E., and Harrington M. How research can help control tuberculosis. Int J Tuberc Lung Dis 13 (2009) 558-568
207. Treatment Action Group & Stop TB Partnership. Tuberculosis Research & Development: 2009 Report on Tuberculosis Research Funding Trends, 2005-2008 (2009), Treatment Action Group, New York
208. Keeler E., Perkins M.D., Small P., et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 444 suppl 1 (2006) 49-57
209. Dowdy D.W., and Chaisson R.E. The persistence of tuberculosis in the age of DOTS: reassessing the effect of case detection. Bull World Health Organ 87 (2009) 296-304
210. Dowdy D.W., Chaisson R.E., Maartens G., Corbett E.L., and Dorman S.E. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci USA 105 (2008) 11293-11298
211. Dowdy D.W., Chaisson R.E., Moulton L.H., and Dorman S.E. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS 20 (2006) 751-762
212. Dowdy D.W., Lourenco M.C., Cavalcante S.C., et al. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults. PLoS One 3 (2008) e4057
213. Abu-Raddad L.J., Sabatelli L., Achterberg J.T., et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 106 (2009) 13980-13985
214. Currie C.S., Floyd K., Williams B.G., and Dye C. Cost, affordability and cost-effectiveness of strategies to control tuberculosis in countries with high HIV prevalence. BMC Public Health 5 (2005) 130
215. Basu S., Friedland G.H., Medlock J., et al. Averting epidemics of extensively drug-resistant tuberculosis. Proc Natl Acad Sci USA 106 (2009) 7672-7677
216. Oxlade O., Schwartzman K., Behr M., et al. Global tuberculosis trends: a reflection of changes in tuberculosis control or in population health?. Int J Tuberc Lung Dis 13 (2009) 1238-1246
217. Lönnroth K., Jaramillo E., Williams B.G., Dye C., and Raviglione M. Drivers of tuberculosis epidemics: the role of risk factors and social determinants. Soc Sci Med 68 (2009) 2240-2246
218. Yew W.W., Chan C.K., Leung C.C., et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 124 (2003) 1476-1481